Type 2 diabetes therapy. A pathophysiologically based approach.
The dramatic increase in the number of classes of oral antidiabetic agents has provided physicians with more tools to help patients manage type 2 diabetes. Of course, glycemic control must remain paramount when choosing an oral agent. However, the mechanism of action of an agent, its side effect profile, and the potential for various nonglycemic benefits may help determine which is the best drug for an individual patient.
Mayerson
Adam B
AB
Yale University School of Medicine, 333 Cedar St, TMP 534, PO Box 208020, New Haven, CT 06520-8020, USA.
Inzucchi
Silvio E
SE
D001549:Benzamides / Q000627:therapeutic use; D001645:Biguanides / Q000627:therapeutic use; D003924:Diabetes Mellitus, Type 2 / Q000188:drug therapy* / Q000503:physiopathology; D006801:Humans; D007004:Hypoglycemic Agents / Q000627:therapeutic use*; D013453:Sulfonylurea Compounds / Q000627:therapeutic use; D013844:Thiazoles / Q000627:therapeutic use; D045162:Thiazolidinediones; D000520:alpha-Glucosidases / Q000627:therapeutic use
D001549:Benzamides; D001645:Biguanides; D007004:Hypoglycemic Agents; D013453:Sulfonylurea Compounds; D013844:Thiazoles; D045162:Thiazolidinediones; C030516:meglitinide; C089946:2,4-thiazolidinedione; D000520:alpha-Glucosidases